Results 61 to 70 of about 19,009 (196)

Decitabine Increases the Transcription of RIG-I Gene to Suppress the Replication of Feline Calicivirus and Canine Influenza Virus

open access: yesMicroorganisms
Developing novel antiviral drugs has always been a significant forefront in biological medicine research. Antiviral drugs can be extracted, purified, and synthesized from various biological sources and by different methods.
Shaotang Ye   +7 more
doaj   +1 more source

Cell‐Based Micro/Nanorobots: From Living Carriers to Living Therapeutic Specialists

open access: yesSmartBot, EarlyView.
Cell‐based micro/nanorobots integrate evolutionarily acquired biological intelligence with engineered capabilities, offering new opportunities for precision medicine in vivo. However, the complex physiological environments of different organs pose significant challenges to their clinical translation.
Junfeng Wu   +12 more
wiley   +1 more source

Decitabine promotes efficient erythroid differentiation from transduced CD34+ cells.

open access: yes, 2014
(a) To evaluate decitabine effects on erythroid differentiation and transduction efficiency, we transduced human CD34+ cells with a GFP-expressing HIV-1 vector following 48-hour prestimulation with 0.5 µM decitabine.
Yogen Saunthararajah (320626)   +4 more
core   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick   +7 more
wiley   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

open access: yesAndrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis   +3 more
wiley   +1 more source

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

open access: yesMolecular Oncology
Hypermethylation of tumor suppressor genes is a hallmark of leukemia. The hypomethylating agent decitabine covalently binds, and degrades DNA (cytosine‐5)‐methyltransferase 1 (DNMT1).
Luisa Brock   +10 more
doaj   +1 more source

New lipid nanocapsules for decitabine encapsulation [PDF]

open access: yes, 2016
Introduction:Currently decitabine, an antimetabolite agent is approved for acute myeloid leukemia in old patients and is administered via intra-venous (IV) route.
Roger, Emilie   +3 more
core   +2 more sources

Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. [PDF]

open access: yesPLoS ONE, 2014
Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established.
Xiao Li   +12 more
doaj   +1 more source

Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease

open access: yesCancer Management and Research, 2019
Qing Ya Wang,* Yuan Li,* Ze Yin Liang, Yue Yin, Wei Liu, Qian Wang, Yu Jun Dong, Yu Hua Sun, Wei Lin Xu, Han Yun Ren Department of Hematology, Peking University First Hospital, Peking University, Beijing, People’s Republic of China*These authors ...
Wang QY   +9 more
doaj  

Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and German MDS Study Group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy